
AstraZeneca Pharma (ASTRAZEN) | Stock Overview & Key Data
AstraZeneca Pharma Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹10,691.00 on June 13, 2025
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Dividend Information
Peer Performance Comparison
Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
---|---|---|---|---|---|---|---|---|---|
AstraZeneca Pharma ASTRAZEN | 218.09B Large-cap | -1.23% | -3.75% | 7.35% | 16.40% | 22.08% | 31.01% | 186.16% | 164.33% |
Sun Pharmaceutical SUNPHARMA | 3.84T Large-cap | -2.63% | -5.12% | -10.20% | -8.38% | -16.03% | -8.55% | 73.73% | 198.65% |
Divi's Laboratories DIVISLAB | 1.63T Large-cap | -7.03% | -14.75% | -0.77% | -0.41% | -2.61% | 22.45% | 58.73% | 91.42% |
Torrent TORNTPHARM | 1.21T Large-cap | -2.85% | 7.55% | 12.16% | 11.91% | 4.52% | 7.03% | 132.03% | 25.86% |
Cipla CIPLA | 1.20T Large-cap | -1.18% | -0.22% | -0.12% | 1.79% | 0.38% | 3.58% | 45.16% | 93.18% |
Mankind Pharma MANKIND | 1.05T Large-cap | -3.87% | 1.46% | 1.13% | -1.40% | -14.37% | 15.49% | 76.92% | 76.92% |
Ownership & Short Interest
AstraZeneca Pharma Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in AstraZeneca Pharma would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ASTRAZEN's 52-week high and low?
- In the last 52 weeks, AstraZeneca Pharma reached a high of ₹10,691.00 (on June 13, 2025) and a low of ₹6,220.00 (on November 21, 2024).
- What is the market cap and P/E ratio for ASTRAZEN?
- Curious about AstraZeneca Pharma's size and valuation? Its market capitalization stands at 218.09B. When it comes to valuation, the P/E ratio (trailing twelve months) is 189.89, and the forward P/E (looking ahead) is N/A.
- Does ASTRAZEN pay dividends? If so, what's the yield?
- Yes, AstraZeneca Pharma is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.34%, and the company has paid an average of ₹24.00 per share annually over the past 3 years.
- Who are AstraZeneca Pharma's main competitors or similar companies to consider before investing?
When looking at AstraZeneca Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.84T Healthcare Drug Manufacturers - Specialty & Generic -8.55% 73.73% Divi's Laboratories
DIVISLAB1.63T Healthcare Drug Manufacturers - Specialty & Generic 22.45% 58.73% Torrent
TORNTPHARM1.21T Healthcare Drug Manufacturers - Specialty & Generic 7.03% 132.03% Cipla
CIPLA1.20T Healthcare Drug Manufacturers - Specialty & Generic 3.58% 45.16% Mankind Pharma
MANKIND1.05T Healthcare Drug Manufacturers - Specialty & Generic 15.49% 76.92% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for AstraZeneca Pharma India Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of AstraZeneca Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 15.62%, the Debt to Equity ratio from the most recent quarter is 4.64, and its Gross Profit Margin stands at 45.97%.
- What is the recent revenue and earnings growth for ASTRAZEN?
- Looking at AstraZeneca Pharma's growth, its revenue over the trailing twelve months (TTM) was INR17B. Compared to the same quarter last year (YoY), quarterly revenue grew by 25.40%, and quarterly earnings saw a YoY growth of 47.50%.
- How much of ASTRAZEN stock is held by insiders and institutions?
- Wondering who owns AstraZeneca Pharma stock? Company insiders (like executives and directors) hold about 81.59% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 5.84%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.